Chemed Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.8%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$2.7Bnext fiscal year
FY EPS (est.)
$25.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 27 Oct 2026 |
Monitoring Framework
Key Performance Indicators
VITAS Average Daily Census (ADC) Quarterly22.7KTarget: 4.5% to 5.5% growth for FY 2026
VITAS Admissions Quarterly19.4K
Roto-Rooter Paid Lead Mix Quarterly53.4
Watch Items
- Medicare Cap Cushion in Florida Combined ProgramAction: Rebalance referral mix between short-length-of-stay hospital admissions and long-length-of-stay non-hospital pre-admissions.
- Roto-Rooter Marketing Spend and Paid Search CostsAction: Optimize digital customer acquisition channels and adjust pricing to offset Google algorithm-driven lead generation headwinds.
Research as of 19 Jun 2026